Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
It is Q-RNA’s mission to develop its novel drug target and discovery systems and use them to discover and optimize therapeutics to treat Alzheimer’s disease (AD), a disorder with a large unmet medical need. With its initial focus on Alzheimer’s disease, the Company will begin with a library of anti-amyloid compounds designed by a former founder of Neurochem, Inc. (NRMX) to dramatically improve on the compounds that Neurochem currently has in Phase II/III testing. In moving from a discovery to an integrated drug development company, Q-RNA believes that it can develop discovery tools and therapeutics for other amyloid or protein misfolding diseases including Parkinson’s disease, type II diabetes, and possibly ( www.q-rna.com )
Q-RNA , Inc.
3960 Broadway Suite 407
New York, New York 10032
USA
Tel: (212) 568-0365
Fax: (212) 568-0469